A group of treatments, called PCSK9 inhibitors, are known to help reduce LDL cholesterol levels. However, these are currently all given as injections, which we know may not be convenient for some people. New, easy and convenient treatment options are needed to support those living with ASCVD or at risk for ASCVD-related events.

This study is looking at an oral PCSK9 inhibitor called AZD0780. We want to find out whether it may help to reduce LDL cholesterol levels and the risk of cardiovascular-related events or medical procedures. By taking part in this study, you’re helping us look for new ways to improve care and outcomes for people like you.